XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 43,141 $ 718,652 $ 283,266 $ 1,065,685
General and administrative 447,360 272,614 1,003,941 839,934
Stock based compensation expense 46,723 51,050 69,123 825,608
Total operating expenses 537,224 1,042,316 1,356,330 2,731,227
Loss from operations (537,224) (1,042,316) (1,356,330) (2,731,227)
Other expenses:        
Interest expense (54,480) (84,217) (106,515) (171,627)
Debt discount and intangible amortization (42,336) (17,103) (134,581) (17,103)
Total other expenses 96,816 101,320 241,096 188,730
Net loss before provision for income taxes (634,040) (1,143,636) (1,597,426) (2,919,957)
Provision for income taxes
NET LOSS (634,040) (1,143,636) (1,597,426) (2,919,957)
Net loss attributable to the non-controlling interest 11,691 246,935 62,807 401,549
NET LOSS ATTRIBUTABLE TO BIOXYTRAN $ (622,349) $ (896,701) $ (1,534,619) $ (2,518,408)
Loss per Common share, basic and diluted $ (0.01) $ (0.01) $ (0.01) $ (0.02)
Weighted average number of Common shares outstanding, basic and diluted 110,840,998 103,371,579 110,840,998 101,753,891